[1] |
Rastogi A, Bhatt N, Rossetti S, et al. Management of hyperphosphatemia in end-stage renal disease[J]. J Ren Nutr, 2021, 31(1): 21-34.
doi: 10.1053/j.jrn.2020.02.003
URL
|
[2] |
Tsuchiya K, Akihisa T. The importance of phosphate control in chronic kidney disease[J]. Nutrients, 2021, 13(5): 1670.
doi: 10.3390/nu13051670
URL
|
[3] |
李花, 黄晓敏, 张春燕, 等. 血清氨基末端脑钠肽前体水平初筛腹膜透析患者容量超负荷的价值[J]. 内科理论与实践, 2023, 18(3): 157-164.
|
[4] |
Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study[J]. Atherosclerosis, 1997, 132(2): 245-250.
doi: 10.1016/s0021-9150(97)00106-8
pmid: 9242971
|
[5] |
Huynh K. Coronary artery disease: coronary artery calcium testing[J]. Nat Rev Cardiol, 2017, 14(11): 634.
doi: 10.1038/nrcardio.2017.146
pmid: 28905867
|
[6] |
Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder[J]. Ann Intern Med, 2018, 20, 168(6): 422-430.
doi: 10.7326/M17-2640
pmid: 29459980
|
[7] |
Bello AK, Okpechi IG, Osman MA, et al. Epidemiology of peritoneal dialysis outcomes[J]. Nat Rev Nephrol, 2022, 18(12): 779-793.
doi: 10.1038/s41581-022-00623-7
pmid: 36114414
|
[8] |
Fusaro M, Cozzolino M, Plebani M, et al. Sevelamer use, vitamin K levels, vascular calcifications, and vertebral fractures in hemodialysis patients[J]. J Bone Miner Res, 2021, 36(3): 500-509.
doi: 10.1002/jbmr.4214
pmid: 33188702
|
[9] |
Wang AY, Pasch A, Wong CK, et al. Long-term effects of sevelamer on vascular calcification, arterial stiffness, and calcification propensity in patients receiving peritoneal dialysis[J]. Kidney Med, 2021, 4(2): 100384.
|
[10] |
Ogata H, Fukagawa M, Hirakata H, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis[J]. JAMA, 2021, 325(19): 1946-1954.
doi: 10.1001/jama.2021.4807
URL
|
[11] |
Ohno M, Ohashi H, Oda H, et al. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis[J]. Perit Dial Int, 2013, 33(3): 297-303.
doi: 10.3747/pdi.2012.00600
URL
|
[12] |
Sprague SM, Ross EA, Nath SD, et al. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients[J]. Clin Nephrol, 2009, 72(4): 252-258.
doi: 10.5414/cnp72252
pmid: 19825330
|
[13] |
Kasai S, Sato K, Murata Y, et al. Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis[J]. Ther Apher Dial, 2012, 16(4): 341-349.
doi: 10.1111/tap.2012.16.issue-4
URL
|
[14] |
Phannajit J, Wonghakaeo N, Takkavatakarn K, et al. The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients[J]. J Nephrol, 2022, 35(2): 473-491.
doi: 10.1007/s40620-021-01065-3
|
[15] |
Duque EJ, Elias RM, Moysés RMA. Parathyroid hormone[J]. Toxins (Basel), 2020, 12(3): 189.
doi: 10.3390/toxins12030189
URL
|
[16] |
Torres PU, Troya MI, Dauverge M, et al. Independent effects of parathyroid hormone and phosphate levels on hard outcomes in non-dialysis patients[J]. Nephrol Dial Transplant, 2022, 37(4): 613-616.
doi: 10.1093/ndt/gfab308
URL
|
[17] |
Salusky IB, Goodman WG, Sahney S, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols[J]. J Am Soc Nephrol, 2005, 16(8): 2501-2508.
pmid: 15944337
|
[18] |
Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD[J]. J Am Soc Nephrol, 2012, 23(8): 1407-1415.
doi: 10.1681/ASN.2012030223
pmid: 22822075
|
[19] |
Filiopoulos V, Koutis I, Trompouki S, et al. Lanthanum carbonate versus sevelamer hydrochloride[J]. Ther Apher Dial, 2011, 15(1): 20-27.
doi: 10.1111/tap.2011.15.issue-1
URL
|
[20] |
Rodríguez-Palomares JR, de Arriba G, Gómez L, et al. Lanthan Lanthanum carbonate and peritoneal catheter dysfunction[J]. Nefrologia, 2012, 32(3): 415-416.
doi: 10.3265/Nefrologia.pre2012.Feb.11341
pmid: 22592438
|